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Background: It is unclear whether the results of osteochondral transplant using autografts or allografts for talar osteochondral
defect are equivalent.
Purpose: A systematic review of the literature was conducted to compare allografts and autografts in terms of patient-reported
outcome measures (PROMs), MRI findings, and complications.
Study Design: Systematic review; Level of evidence, 4.
Methods: This study was conducted according to the PRISMA guidelines. The literature search was conducted in February 2021.
All studies investigating the outcomes of allograft and/or autograft osteochondral transplant as management for osteochondral
defects of the talus were accessed. The outcomes of interest were visual analog scale (VAS) score for pain, American Orthopae-
dic Foot and Ankle Society (AOFAS) score, and Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score.
Data concerning the rates of failure and revision surgery were also collected. Continuous data were analyzed using the mean dif-
ference (MD), whereas binary data were evaluated with the odds ratio (OR) effect measure.
Results: Data from 40 studies (1174 procedures) with a mean follow-up of 46.5 6 25 months were retrieved. There was compa-
rability concerning the length of follow-up, male to female ratio, mean age, body mass index, defect size, VAS score, and AOFAS
score (P . .1) between the groups at baseline. At the last follow-up, the MOCART (MD, 10.5; P = .04) and AOFAS (MD, 4.8; P =
.04) scores were better in the autograft group. The VAS score was similar between the 2 groups (P = .4). At the last follow-up,
autografts demonstrated lower rate of revision surgery (OR, 7.2; P \ .0001) and failure (OR, 5.1; P \ .0001).
Conclusion: Based on the main findings of the present systematic review, talar osteochondral transplant using allografts was
associated with higher rates of failure and revision compared with autografts at midterm follow-up.
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Osteochondral lesions of the talus are common.50 Given the
avascular and hypocellular nature of articular cartilage, the
management of talar osteochondral lesions is challeng-
ing.15,49 Several surgical procedures have been
described.57,66 Smaller defects up to 1.5 cm2 can be treated
arthroscopically using the microfractures technique.4,52,74
For larger defects, osteochondral transplant has been com-
monly used.16,69 Osteochondral transplant can be performed
using single or multiple plugs (mosaicplasty).13,68 Indica-
tions for osteochondral transplant are full-thickness
symptomatic defects of 1 cm2 up to approximately
4 cm2.23,24 Both osteochondral allografts and autografts
can be used.39,47 Common donor sites for autologous osteo-
chondral plugs are the anterosuperior condyle region and
the lateral aspect of the intercondylar notch of the ipsilat-
eral femur.68 The use of allografts avoids donor site morbid-
ity.9,76 Several clinical studies have evaluated the outcomes
of autografts and allografts.** Whether osteochondral
transplant using autografts performs better than that using
allografts has not been fully clarified. The present study
updates current evidence concerning the use of allografts
and autografts for osteochondral transplant in talar
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osteochondral defects at midterm follow-up. A systematic
review of the literature was conducted to compare allografts
versus autografts in terms of patient-reported outcome
measures (PROMs), MRI findings, and complications.
METHODS
Search Strategy
This study was conducted according to the PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines.51 The PICO algorithm was as
follows:
 P (Problem): talus osteochondral defects
 I (Intervention): osteochondral transplant
 C (Comparison): autograft versus allograft
 O (Outcomes): clinical scores, MRI findings, and
complications
Data Source
The literature search was conducted in February 2021.
Two independent authors (F.M. and H.S.) accessed the
main online databases: PubMed, Google Scholar, Embase,
and Scopus. The following keywords were used in combina-
tion: talus, ankle, chondral, cartilage, articular, osteochon-
dral, damage, defect, injury, chondropathy, pain,
autologous, allograft, autograft, transplantation, therapy,
management, surgery, outcomes, failure, revision, reopera-
tion, recurrence. The same reviewers selected the articles
of interest and accessed the full-text. The bibliographies
were also checked. Disagreements were solved by a third
author (N.M.).
Eligibility Criteria
All studies investigating the surgical outcomes of allograft
and/or autograft osteochondral transplant as management
for osteochondral defects of the talus were accessed. Given
the authors’ language capabilities, articles in English, Ger-
man, Italian, French, and Spanish were considered. Stud-
ies with level of evidence 1 to 4, according to the Oxford
Centre for Evidence-Based Medicine,37 were eligible. Reg-
istries, letters, abstracts, reviews, editorials, and opinions
were not considered. Animal, computational, biomechan-
ics, and in vitro studies were excluded. Studies augment-
ing autologous matrix-induced chondrogenesis (AMIC) or
matrix-induced autologous chondrocyte implantation
(mACI) with less committed cells (eg, mesenchymal stem
cells) were not considered. Studies reporting data on
patients with end-stage joint osteoarthritis were not con-
sidered. Missing data under the outcomes of interest war-
ranted exclusion from this study.
Data Extraction
Two authors (F.M. and H.S.) separately performed data
extraction. Study generalities (author, year, journal, study
design) and length of follow-up were retrieved. Baseline
patient data were collected: length of symptoms before
intervention, number of procedures, mean body mass index
(BMI), mean age, sex, and mean defect size. Further, data
concerning the following scores were retrieved: visual ana-
log scale (VAS) for pain, American Orthopaedic Foot and
Ankle Society (AOFAS),75 and Magnetic Resonance Obser-
vation of Cartilage Repair Tissue (MOCART).48 Rate of
failures and revision surgeries were also collected.
Methodological Quality Assessment
The methodological quality assessment was performed by
2 independent authors (F.M. and H.S.). The risk of bias
graph tool of the Review Manager Software (The Nordic
Cochrane Collaboration) was used. Selection, detection,
attrition, reporting, and other sources of bias were consid-
ered for evaluation.
Statistical Analysis
The statistical analyses were performed by the main
author (F.M.) using the IBM SPSS Version 25 program.
Continuous data were reported as mean difference (MD),
whereas binary variables were reported using the odds
ratio (OR) effect measure. The confidence interval (CI)
was set at 95%. We performed t tests and x2 tests for con-
tinuous and binary data, respectively, with P \ .05 consid-
ered statistically significant.
The meta-analyses were performed using Editorial
Manager Software Version 5.3 (The Nordic Cochrane Col-
laboration). Dichotomous data were analyzed through the
Mantel-Haenszel method and OR effect measure. The CI
was set at 95% in all comparisons. A fixed model effect
was set as default. If moderate or high heterogeneity was
detected, a random model effect was adopted. Heterogene-
ity was evaluated through Higgins I2 and x2 tests. Values
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of Higgins I2 were interpreted as low (\30%), moderate




The literature search resulted in 357 articles. Of them, 104
were duplicates. A further 213 articles were excluded
because of incompatibility with the inclusion criteria: not
matching the topic (n = 139), not focusing on the talus
(n = 17), study design (n = 21), not reporting quantitative
data under the outcomes of interest (n = 11), augmented
with other cells (n = 7), reporting data on patients with
end-stage joint degeneration (n = 5), language limitations
(n = 1), and other (n = 12). This left 40 articles for the pres-
ent study: 35 retrospective and 4 prospective studies and 1
randomized clinical trial. The literature search results are
shown in Figure 1.
Methodological Quality Assessment
Given the retrospective design of 85% (35/40) of the
included studies, the risk of selection bias was moderate-
high. Given the overall lack of blinding, detection bias
was high. The risk of attrition and reporting bias among
all included studies was moderate, as was the risk of other
bias. The overall quality of the methodological assessment
was fair. The risk of bias graph is shown in Figure 2.
Patient Characteristics
Data from 1174 procedures, with a mean follow-up of 46.5
6 25 months, were retrieved. Study generalities and
patient characteristics are shown in Table 1. There was
no difference at baseline between the allograft and auto-
graft groups (Table 2) concerning the duration of symp-
toms before surgery (P = .05), length of follow-up (P = .6),
male to female ratio (P = .5), mean age (P = .4), mean
BMI (P = .1), defect size (P = .6), VAS score (P = .8), and
AOFAS score (P = .1).
Outcomes of Interest
At last follow-up, the autograft group had higher MOCART
scores (MD, 10.5; P = .04). Similarly, the AOFAS score was
higher in the autograft group (MD, 4.8; P = .04). The VAS
score was similar between the 2 groups (P = .4) (Table 3).
Complications
The autograft group demonstrated lower rates of revision
surgery (OR, 7.2; P \ .0001) and failure (OR, 5.1; P \
.0001) (Table 4).
Figure 1. Flow chart of the literature search.
Figure 2. Methodological quality assessment.
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Meta-analysis
Two comparative studies including 77 patients were
included in the meta-analysis.3,70 We noted statistically
significant lower rates of revision surgery (OR, 12.0; P =
.02) and failure (OR, 13.8; P = .004) in the autograft group.
The forest plots are shown in Figure 3.
DISCUSSION
According to the main findings of the present study, osteo-
chondral transplant for osteochondral defects of the talus
using autografts or allograft evidenced similar VAS and
AOFAS scores at midterm follow-up. However, given the
lower rates of failure and revision, autografts should be
preferred during primary surgeries for osteochondral
defects of the talus. The primary use of allograft should
probably be reserved for patients who do not have a suit-
able donor site.
Osteochondral autograft transplant has been used for
small to medium-sized defects of the talus, with a rate of
satisfaction up to 95% for primary procedures.41,67 Osteo-
chondral autograft transplant has been used in revision
settings as well, with considerable improvement of AOFAS
and VAS scores.42,78 Allografts show a higher rate of
TABLE 1
Generalities and Descriptions of the Included Studiesa
Lead Author (Year) Journal Design Follow-up, mo Treatment Procedures Female, % Mean Age, y
Adams2 (2011) J Bone Joint Surg Am Retrospective 48 Osteochondral allograft transplant 8 62.5 31.4
Adams1 (2018) Foot Ankle Int Prospective 55.0 Osteochondral allograft transplant 14 42.9 40.0
Ahmad3 (2016) Foot Ankle Int Randomized 40.5 Osteochondral allograft transplant 16 37.5 39.7
35.2 Osteochondral autograft transplant 20 45.0 41.3
El-Rashidy12 (2011) J Bone Joint Surg Am Retrospective 37.7 Osteochondral allograft transplant 38 42.1 44.2
Emre13 (2012) J Foot Ankle Surg Retrospective 16.8 Mosaicplasty 32 9.4 27.5
de l’Escalopier10 (2015) Orthop Traumatol Surg Res Retrospective 76.0 Mosaicplasty 37 33.0 21.6
Fraser16 (2016) Knee Surg Sports
Traumatol Arthrosc
Retrospective 70.8 Osteochondral autograft transplant 36 33.3 31.0
Gaul19 (2019) Foot Ankle Int Retrospective 116.4 Osteochondral allograft transplant 20 47.0 34.7
Gaul18 (2018) Foot Ankle Int Retrospective 123.6 Osteochondral allograft transplant 20 55.0 43.6
Gautier20 (2002) J Bone Joint Surg Br Retrospective 24.0 Osteochondral autograft transplant 11 66.5 32.0
Georgiannos21 (2016) Knee Surg Sports
Traumatol Arthrosc
Retrospective 66 Osteochondral autograft transplant 48 19.5 36
Gobbi22 (2006) Arthroscopy Prospective 53.0 Control group 10 40.0 24.0
Control group 11 45.5 32.0
Osteochondral autograft transplant 12 33.3 27.8
Gül28 (2016) J Foot Ankle Surg Retrospective 30.5 Osteochondral autograft transplant 15 33.3 32.6
28.9 Osteochondral autograft transplant 13 8.3 36.7
Guney29 (2016) Knee Surg Sports
Traumatol Arthrosc
Prospective 47.3 Control group 19 37.4 47, 4
40.4 Control group 22 43.9 50.0
30.1 Mosaicplasty 13 37.6 15.4
Haleem33 (2014) Am J Sports Med Retrospective 93.0 Osteochondral autograft transplant 14 50.0 42.8
85.3 Osteochondral autograft transplant 28 39.3 44.1
Haasper30 (2008) Arch Orthop Trauma Surg Retrospective 24.0 Mosaicplasty 14 57.1 24.8
Hahn32 (2010) Foot Ankle Int Retrospective 47.9 Osteochondral allograft transplant 13 61.5 30.4
Hangody34 (1997) Foot Ankle Int Retrospective 19.0 Mosaicplasty 11 NR 25.1
Hangody35 (2001) Foot Ankle Int Retrospective 50.4 Mosaicplasty 36 NR 27.0
Imhoff38 (2011) Am J Sports Med Retrospective 84.0 Osteochondral autograft transplant 26 46.2 33.0
Jackson39 (2019) J Foot Ankle Surg Retrospective 21.0 Osteochondral allograft transplant 31 9.7 33.6
Kreuz42 (2006) Am J Sports Med Retrospective 48.9 Mosaicplasty 35 48.6 30.9
Lee44 (2003) Foot Ankle Int Retrospective 36.0 Mosaicplasty 18 5.6 22.7
Li45 (2017) BMC Musculoskelet Disord Retrospective 21.2 Osteochondral autograft transplant 11 63.6 55.4
Liu46 (2011) Foot Ankle Int Prospective 36.3 Osteochondral autograft transplant 16 37.5 33.9
Liu47 (2020) Foot Ankle Int Retrospective 18.0 Osteochondral autograft transplant 14 21.4 29.6
Nguyen55 (2019) Am J Sports Med Retrospective 44.7 Osteochondral autograft transplant 38 0.0 26.0
Orr56 (2017) Foot Ankle Spec Retrospective 28.5 Osteochondral allograft transplant 8 0.0 34.4
Park58 (2018) Am J Sports Med Retrospective 71.4 Osteochondral autograft transplant 18 41.6 NR
Osteochondral autograft transplant 28 41.6 NR
Park57 (2020) Bone Joint J Retrospective 22.0 Osteochondral allograft transplant 25 40.0 19.6
Paul59 (2012) Am J Sports Med Retrospective 60.0 Osteochondral autograft transplant 131 38.2 31.0
Ross64 (2016) Arthroscopy Retrospective 51.0 Osteochondral autograft transplant 76 34.2 35.8
Sabaghzadeh65 (2020) Chin J Traumatol Retrospective Mosaicplasty 19 42.1 43.0
Sadlik66 (2017) Foot Ankle Surg Retrospective 46.4 Osteochondral autologous transposition 10 40.0 37.0
Shimozono69 (2018) Am J Sports Med Retrospective 52.0 Osteochondral autograft transplant 63 42.9 36.0
45.0 Osteochondral autograft transplant 31 32.3 34.0
Shimozono70 (2018) J Bone Joint Surg Am Retrospective 26.3 Osteochondral autograft transplant 25 64.0 38.4
22.3 Osteochondral allograft transplant 16 37.5 43.6
Woelfle77 (2013) Knee Surg Sports
Traumatol Arthrosc
Retrospective 29.0 Osteochondral autograft transplant 32 24.5 46.9
Yoon78 (2014) Am J Sports Med Retrospective 45.0 Osteochondral autograft transplant 22 31.8 37.1
Retrospective 50.0 Control group 22 18.2 41.6
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failure and higher costs, greater risk of disease transmis-
sion, and limited availability, whereas the autologous tech-
niques can entail donor site morbidity.14 The effect of
donor site morbidity on outcomes has not been fully clari-
fied. Considering low-weightbearing, dimensional proper-
ties and surface curvature, only 3 harvest sites are
available within the knee: the lateral side of the intercon-
dylar notch, the superomedial trochlea, and the superolat-
eral trochlea.27,36,63 In a systematic review by Bexkens
et al7 that included 190 patients, the rate of donor site mor-
bidity was 7.8% (10/128 patients). Of those patients, 7% (9/
128 patients) reported knee pain during activity and 0.8%
(1/128 patients) reported locking episodes. Shimozono
et al,71 in a meta-analysis of 24 studies (915 procedures),
estimated the rate of donor site morbidity to be from
6.7% to 10.8%. Nakagawa et al53 investigated the clinical
outcomes of donor sites in the knee after osteochondral
autograft transplant. Those investigators found that 34 of
40 patients (85%) were asymptomatic at a mean follow-
up of 43.1 months.
Despite the encouraging results with autografts, the use
of allografts has become more prevalent to avoid donor site
morbidity. Studies have shown that allografts achieve simi-
lar clinical outcomes as autografts and avoid donor site mor-
bidity but have a greater rate of revision and failure.12,26
Two studies compared allografts versus autografts for osteo-
chondral defects of the talus. Ahmad et al3 conducted a pro-
spective study comparing 16 autograft procedures with
grafts from the ipsilateral femoral condyle versus 20 fresh
size-matched allografts; the mean VAS scores improved
similarly in both groups. Shimozono et al70 retrospectively
evaluated 25 patients treated with autografts versus 16
patients treated with allografts for talar defects and found
that AOFAS and MOCART scores were better in the auto-
graft group. Both of these studies found higher rates of fail-
ure and revision surgery in the allograft group.
TABLE 2
Characteristics of the 2 Cohorts at Baselinea
Allograft Autograft MD P
Procedures, n 219 955
Follow-up, mo 50.8 6 34.3 46.0 6 21.6 4.7 .6
Duration of symptoms, mo 54.3 6 39.5 21.9 6 16.8 32.4 .05
Female, % 39.6 6 18.5 36.1 6 16.3 3.5 .5
Mean age, y 36.0 6 7.0 33.5 6 8.3 2.5 .4
Body mass index 27.9 6 2.4 25.0 6 1.4 1.9 .1
Defect size, cm2 1.8 6 0.8 2.6 6 4.3 –0.9 .6
VAS score 6.9 6 0.9 6.7 6 0.9 0.1 .8
AOFAS score 58.8 6 13.8 51.5 6 9.1 7.3 .1
Lesion site, % (n/N)
Medial 72.9 (102/140) 72.4 (417/576)
Central 1.4 (2/140) 0.5 (3/576)
Lateral 25.7 (36/140) 27.1 (156/576)
aValues for allograft and autograft are expressed as mean 6 SD unless otherwise noted. AOFAS, American Orthopaedic Foot and Ankle
Society; MD, mean difference; VAS, visual analog scale.
TABLE 3
Results of VAS, MOCART, and AOFAS Scoresa
Score Allograft Autograft MD P
VAS 2.3 6 1.3 2.5 6 1.3 0.2 .4
MOCART 72.5 6 4.2 83.0 6 8.7 10.5 .04
AOFAS 81.6 6 6.0 86.4 6 5.6 4.8 .04
aAOFAS, American Orthopaedic Foot and Ankle Society; MD, mean difference; MOCART, Magnetic Resonance Observation of Cartilage
Repair Tissue; VAS, visual analog scale.
TABLE 4
Results of Complications
Endpoint Allograft, % (n/N) Autograft, % (n/N) OR 95% CI P
Revision 44.9 (58/129) 10.2 (50/490) 7.19 4.5665-11.3167 \.0001
Failure 14.7 (24/163) 3.3 (16/490) 5.08 2.6263-9.8367 \.0001
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The present study found a rate of failure of 14.7% (24/
163 patients). This finding agrees with previous evidence
of failure rates between 12% and 30%. Ahmad et al3 found
that 18.8% of allografts did not heal properly as shown on
computed tomography scans or plain radiographs after 6
months. Gross et al26 reported fragmentation and resorp-
tion of the allograft in one-third of patients (3/9). Haene
et al31 evaluated the failure rate of allografts in 16 patients
at 48 months of follow-up. Those investigators evidenced
failure in graft incorporation in 13% (2/16), osteolysis in
31% (5/16), and cysts in 50% (8/16) of patients at 4 years.
The higher rate of failure in allografts may derive from
immune-mediated mechanisms.54 Immune responses similar
to those implicated in allogenic organ transplant rejections
have been documented in human and animal osteochondral
allograft transplant.17,60,72,73 Sirlin et al72 demonstrated
that 31% (11/36) of patients who underwent allograft implan-
tation in the knee presented anti-human antibody. These
patients had a statistically significant greater rate of edema,
thicker interface, abnormal graft marrow, and surface col-
lapse.72 Pomajzl et al61 demonstrated a substantial loss of
sulfated glycosaminoglycans and osteocalcin in the graft-
host interface, along with a high osteoclast activity. They fur-
ther demonstrated the presence of T-helper, T-cytotoxic, and
NK cells. Moreover, Pomajzl et al demonstrated the presence
of tumor necrosis factor a throughout the allograft. These
features discourage the use of osteochondral allograft trans-
plant. If a suitable harvest site is unavailable, other techni-
ques can be used, such as AMIC, mACI, and matrix-
induced stem cell transplant (mAST); these are feasible and
reliable options that exploit the regenerative potential of
autologous tissue.5,6,8,25,62 Particulated juvenile articular car-
tilage (PJAC) transplant has been also used to manage osteo-
chondral defects of the talus. However, given its limited
evidence and controversial results, PJAC was not included
in this analysis.11,40,43
This study has some limitations. The analyses were per-
formed regardless of the surgical approach (arthroscopy,
mini-arthrotomy, arthrotomy). Furthermore, the limited
number of included articles and procedures may have neg-
atively affected our results. The retrospective design of
most of the studies represents an important limitation;
however, the current literature lacks high-quality studies,
and further investigations are required. Furthermore,
given the lack of studies directly comparing the 2 types
of graft, the meta-analysis collected data from only 2 tri-
als.3,70 Thus, even if no heterogeneity was detected, the
reliability of the results is questionable. Most authors did
not clarify the type of allograft used and did not specify
its provenance or any additional procedures (eg, steriliza-
tion) before transplant. Given the lack of data, primary
and revision surgeries were often mixed, and some authors
combined the surgeries with other procedures. This may
have influenced the results, increasing the risk of selection
bias. Given the lack of data, the analyses were performed
regardless of the cause of the defect or the talar location
of the defect (eg, medial vs lateral). Thus, our results
must be interpreted within the limitations of the present
investigation. Future studies are required to overcome
these limitations.
CONCLUSION
Based on the main findings of the present systematic
review, talar osteochondral transplant using allografts
was associated with higher rates of failure and revision
compared with autografts at midterm follow-up. However,
A
B
Figure 3. Forest plots of the comparison: (A) failures and (B) revision surgeries.
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given the limited published data, the strength of the con-
clusions is weak and further high-quality comparative
studies are required.
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